---
document_datetime: 2025-08-27 08:43:41
document_pages: 19
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/bosulif-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: bosulif-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 11.6069143
conversion_datetime: 2025-12-30 09:54:28.958826
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Bosulif

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| X/0058/G             | This was an application for a group of variations. C.I.6.a - Change(s) to therapeutic indication(s) - | 27/03/2025                          | 02/06/2025                                  | SmPC, Labelling and PL           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | pharmaceutical form Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0062             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                              | 19/12/2024 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0060             | Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on cardiovascular toxicity and to add cardiac failure and cardiac ischaemic events to the list of adverse drug reactions (ADRs) with frequency common, based on an updated safety review. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 21/11/2024 | 02/06/2025 | SmPC and PL | SmPC new text Cardiovascular toxicity Bosulif can cause cardiovascular toxicity including cardiac failure and cardiac ischaemic events. Cardiac failure events occurred more frequently in previously treated patients than in patients with newly diagnosed CML and were more frequent in patients with advanced age or risk factors, including previous medical history of cardiac failure. Cardiac ischaemic events occurred in both previously treated patients and in patients with newly diagnosed CML and were more common in patients with coronary artery disease risk factors, including history of diabetes, body mass index greater than 30, hypertension and vascular disorders. Patients should be monitored for signs and symptoms consistent with cardiac failure and cardiac ischaemia and treated as clinically indicated. Cardiovascular toxicity can also be managed by dose interruption, dose reduction and/or discontinuation of bosutinib. For more information, please refer to the Summary of Product Characteristics. |
| PSUSA/10073 /202403 | Periodic Safety Update EU Single assessment - bosutinib                                                                                                                                                                                                                                                                                                                                                                          | 31/10/2024 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IB/0057   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 01/03/2024   | n/a        |                       |                                                                       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------------------------------------------|
| IAIN/0056 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 16/05/2023   | 22/05/2024 | SmPC and PL           |                                                                       |
| IA/0055   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 09/11/2022   | n/a        |                       |                                                                       |
| IA/0054   | B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13/10/2022   | n/a        |                       |                                                                       |
| II/0050/G | This was an application for a group of variations. (Type II) C.I.4 - Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to reflect results from studies B1871039 (specific obligation) and B1871040 (post-authorisation safety study); The Package Leaflet is updated accordingly. An updated RMP (version 6.0) has also been submitted. Update of Annex II to remove the specific obligation and conversion of the conditional marketing authorisation into a marketing authorisation not subject to specific obligations. Section 5.1 of the SmPC and Section 6 of the PL are updated accordingly to remove the reference to the conditional marketing authorisation. In addition, the | 27/01/2022   | 07/04/2022 | SmPC, Annex II and PL | Please refer to Scientific Discussion 'Bosulif-H-C-002373-II- 0050/G' |

<div style=\"page-break-after: always\"></div>

|        | product from the list of medicines subject to additional monitoring. (Type IA) A.6 - Update of the ATC code in section 5.1 of the SmPC according to the new WHO classification. In addition, the MAH took the opportunity to update the list of local representatives for Belgium, Luxemburg, Germany and Northern Ireland in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data A.6 - Administrative change - Change in ATC Code/ATC Vet Code C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0051 | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 27/01/2022 | 31/03/2022 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the MA for Bosulif, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. Furthermore, the CHMP confirmed the recommendation adopted in the parallel variation II/50G (EMEA/H/C/002373 /II/0050/G) to grant for Bosulif a Marketing Authorisation |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |             | no longer subject to Specific Obligations.                                                                                                                                                                                  |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0053/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation | 15/03/2022 | n/a        |             |                                                                                                                                                                                                                             |
| IA/0052             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                               | 22/12/2021 | n/a        |             |                                                                                                                                                                                                                             |
| PSUSA/10073 /202103 | Periodic Safety Update EU Single assessment - bosutinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 30/09/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                           |
| II/0048             | Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update safety and efficacy information based on final results from study B18711053 (a recommendation of EMEA/H/C002373/II/25/G). This is an interventional safety and efficacy study covering submission of the long-term experience results secondary endpoints (duration of MMR and CCyR, EFS and OS). The Safety Data pool is also                                                                                                                                                   | 22/07/2021 | 31/03/2022 | SmPC and PL | Efficacy and safety information have been updated in the product information upon available 60 months follow up data for the study B18711053. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                     | updated with results of interventional studies, B18711048 (final CSR submitted in variation II/41) and ongoing studies B18711039 and B18711040 (listed as category 3 studies in the RMP); the Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                              |            |            |             |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| R/0045              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/12/2020 | 11/02/2021 |             |                                                                                                                                            |
| PSUSA/10073 /202003 | Periodic Safety Update EU Single assessment - bosutinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 15/10/2020 | 14/12/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10073/202003. |
| IB/0047/G           | This was an application for a group of variations. B.I.a.3.z - Change in batch size (including batch size ranges) of AS or intermediate - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 11/12/2020 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|         | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor   |            |            |             |                                                                                                                                                                                                                                                                                                             |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0046  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 27/11/2020 | 11/02/2021 | PL          |                                                                                                                                                                                                                                                                                                             |
| II/0043 | Update of section 5.3, of the SmPC in order to update non-clinical information following the final results from the six-month transgenic rasH2 mouse carcinogenicity study, listed as a category 3 in the current approved RMP version 4.5. ; The RMP version 5.0 has also been submitted. The MAH took the opportunity to implement changes resulting from the revision of the SmPC guideline on excipients, applied in the SmPC section 4.4 and in the Package Leaflet                                                                                                                                                                                                                                                                                                                                                                           | 03/09/2020 | 14/12/2020 | SmPC and PL | SmPC new text: 4.4 Special warning and precautions for use Dietary sodium This medicinal product contains less than 1 mmol sodium (23 mg) per 100 mg, 400 mg, or 500 mg tablet. Patients on low sodium diets should be informed that this product is essentially 'sodium-free'. 5.3 Preclinical safety data |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | section 2. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     | /…/ Carcinogenicity Bosutinib was not carcinogenic in the 2-year rat and 6- month rasH2 mouse carcinogenicity studies. The Package Leaflet (PL) is updated accordingly. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0044/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites | 26/08/2020 | n/a |                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         | starting material/reagent/intermediate for AS - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                      |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0041 | Update of sections 4.4 and 5.2 of the SmPC with additional safety and PK data from the recently completed Phase 2 study (B1871048) following a commitment within variation EMEA/H/C/002373/II/0036 and a pooled safety data analysis performed to assess the clinical impact of reduced clearance in Asian population. The MAH takes also the opportunity to make editorial changes on the Package Leaflet C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 23/07/2020 | 14/12/2020 | SmPC and PL | SmPC new text According to population pharmacokinetic analyses, Asians had a lower clearance resulting in increased exposure. Therefore, these patients should be closely monitored for adverse reactions especially in case of dose escalation. No formal studies have been performed to assess the effects of Age, gender and race demographic factors. Population pharmacokinetic analyses in patients with Ph+ leukaemia or malignant solid tumour and in healthy subjects indicate that there are no clinically relevant effects of age, gender or body weight. Population pharmacokinetic analyses revealed that Asians had a 18% lower clearance corresponding to an approximately 25% increase in bosutinib exposure (AUC). For more information, please refer to the Summary of Product Characteristics. |
| R/0039  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 12/12/2019 | 13/02/2020 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| N/0040  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                             | 13/11/2019 | 13/02/2020 | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10073 /201903   | Periodic Safety Update EU Single assessment - bosutinib                                                                                                                                                                                                                                                                                                                                                                                                             | 03/10/2019   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0036               | Submission of a population pharmacokinetic (popPK) analysis PMAR-884 that was conducted to fulfil a post-authorisation measure (PAM) requested by the CHMP as part of the assessment of Bosulif for the first-line treatment of chronic myelogenous leukaemia (CML) indication (variation EMEA/H/C/002373/II/0025/G). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 18/07/2019   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0037               | Update of sections 4.6 and 5.3 of the SmPC based on final results from An Oral (Gavage) Study of the Effects of PF-05208763 on Pre- and Postnatal Development, Including Maternal Function in Rats listed as a category 3 study in the RMP. The Package leaflet is updated accordingly. The updated RMP version 4.5 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data      | 16/05/2019   | 13/02/2020 | SmPC and PL                      | Women of childbearing potential should be advised to use effective contraception during treatment with bosutinib and for at least 1 month after the last dose and to avoid becoming pregnant while receiving bosutinib. In a rat pre and postnatal development study, there were reduced number of pups born at ≥ 30 mg/kg/day, and increased incidence of total litter loss and decreased growth of offspring after birth occurred at 70 mg/kg/day. The dose at which no adverse development effects were observed (10 mg/kg/day) resulted in exposures equal to 1.3 times and 1.0 times human exposure resulting from the clinical dose of 400 mg and 500 mg, respectively (based on unbound AUC in the respective species). |
| R/0035                | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                             | 13/12/2018   | 18/02/2019 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| II/0030             | Submission of an updated RMP (finally agreed version 4.4) in line with changes requested by the CHMP following variation II/25/G in fulfilment of REC 014; in addition, the MAH took the opportunity to extend the due date of the Specific Obligation (SOB) study of the conditional marketing authorisation. Annex II has been updated accordingly. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   | 18/10/2018   | 18/02/2019   | Annex II   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------|-----------------------------------|
| PSUSA/10073 /201803 | Periodic Safety Update EU Single assessment - bosutinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 04/10/2018   | n/a          |            | PRAC Recommendation - maintenance |
| IB/0033/G           | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation       | 10/09/2018   | n/a          |            |                                   |

<div style=\"page-break-after: always\"></div>

| T/0032    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 11/07/2018   | 02/08/2018   | SmPC, Labelling and PL           |                                                                   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-------------------------------------------------------------------|
| IA/0034   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 11/07/2018   | n/a          |                                  |                                                                   |
| X/0026    | Extension application to add a new strength of 400 mg film-coated tablets Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22/03/2018   | 22/05/2018   | SmPC, Annex II, Labelling and PL |                                                                   |
| II/0025/G | This was an application for a group of variations. Extension of Indication to include treatment of adult patients with newly diagnosed Philadelphia Chromosome positive (Ph+) Chronic Phase (CP) Chronic Myelogenous Leukaemia (CML) for Bosulif based on study AV001. In addition, the MAH updated the SmPC with safety and efficacy information from studies B1871006 and B1871008. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated accordingly. Moreover, the updated RMP version 4.1 was agreed during the procedure. Furthermore, the Annex IIIA is brought in line with | 22/02/2018   | 23/04/2018   | SmPC, Labelling and PL           | Please refer to Scientific Discussion: Bosulif H-2373-II-25- G-AR |

<div style=\"page-break-after: always\"></div>

|         | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0029 | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                           | 05/04/2018 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0028 | Update of section 5.2 of the SmPC following further analyses of the pharmacokinetic (PK) data from Study B1871044 that has been already submitted to the EMA previously. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                           | 15/03/2018 | 22/05/2018 | SmPC                   | Following administration of a single intravenous dose of 120 mg bosutinib to healthy subjects, bosutinib had a mean (% coefficient of variation [CV]) volume of distribution of 2,331 (32) L, suggesting that bosutinib is extensively distributed to extra vascular tissue. In healthy subjects given a single intravenous dose of 120 mg bosutinib, the mean (%CV) terminal elimination half life was 35.5 (24) hours, and the mean (%CV) clearance was 61.9 (26) L/h. |
| R/0027  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                              | 14/12/2017 | 08/02/2018 | SmPC, Labelling and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                     |            |            |             | renewal of the conditional MA for Bosulif, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.                                                                                                                                                                                                                                                                                                                                            |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10073 /201703 | Periodic Safety Update EU Single assessment - bosutinib                                                                             | 28/09/2017 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| R/0023              | Renewal of the marketing authorisation.                                                                                             | 26/01/2017 | 24/03/2017 | SmPC and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Bosulif, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion. |
| PSUSA/10073 /201603 | Periodic Safety Update EU Single assessment - bosutinib                                                                             | 13/10/2016 | 08/12/2016 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10073/201603.                                                                                                                                                                                                                                                                                                                                        |
| IAIN/0021           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                      | 11/05/2016 | 08/12/2016 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0020             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation | 01/02/2016 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0019              | Renewal of the marketing authorisation.                                                                                             | 19/11/2015 | 07/01/2016 |             | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                       | sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Bosulif, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion.                                                                                                                                                                                                                                                                     |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10073 /201503 | Periodic Safety Update EU Single assessment - bosutinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 24/09/2015 | 23/11/2015 | SmPC and PL           | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10073/201503.                                                                                                                                                                                                                                                                                                                        |
| II/0018             | Update of section 5.2 of the SmPC in order to update the Pharmacokinetic properties information after analysis of final study report for study B1871044 (open label, randomised, 2-period crossover study to evaluate absolute bioavailability of bosutinib in healthy subjects) in fulfilment of MEA 005.2; in addition, the Marketing authorisation holder (MAH) took the opportunity to correct minor errors in the Package Leaflet, to combine the SmPC of the 100 mg and 500 mg presentations and to bring the PI in line with the latest QRD template version 9.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 22/10/2015 | 07/01/2016 | SmPC, Annex II and PL | Following administration of a single dose of bosutinib (500 mg) with food in healthy subjects, the absolute bioavailability was 34%.                                                                                                                                                                                                                                                                                                                              |
| II/0014/G           | This was an application for a group of variations. Update of section 4.5 of the SmPC in order to include further information related to concomitant use of Bosulif with CYP3A inhibitors based on the results of Study B1871041, and in order to reflect the results of Study B1871043 submitted to fulfil MEA 003.2 and undertaken to investigate the drug interaction                                                                                                                                                                                                                                                                                                                    | 23/07/2015 | 23/11/2015 | SmPC and PL           | In a study of 20 healthy subjects, in whom a single dose of 125 mg aprepitant (a moderate CYP3A inhibitor) was co administered with a single dose of 500 mg bosutinib under fed conditions, aprepitant increased bosutinib Cmax by 1.5- fold, and bosutinib AUC in plasma by 2.0-fold, as compared with administration of bosutinib alone. In a study of 27 healthy subjects, in whom a single dose of 500 mg bosutinib was co-administered with a single dose of |

<div style=\"page-break-after: always\"></div>

|           | potential with regard to bosutinib being a P-gp inhibitor. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes in the SmPC and Package Leaflet. A revised RMP version 3.1 was agreed during the procedure. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            | 150 mg dabigatran etexilate mesylate (a P-glycoprotein (P- gp) substrate) under fed conditions, bosutinib did not increase Cmax or AUC of dabigatran in plasma, as compared with administration of dabigatran etexilate mesylate alone. The study results indicate that bosutinib does not exhibit clinically relevant P gp inhibitory effects.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0015    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                         | 24/06/2015 | 23/11/2015 |                                                                                                                                                                                                                                                                                                                                                   |
| IB/0016/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                        | 19/05/2015 | n/a        |                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10073 /201409   | Periodic Safety Update EU Single assessment - bosutinib                                                                                       | 12/03/2015   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0010                | Renewal of the marketing authorisation.                                                                                                       | 18/12/2014   | 26/02/2015 |             | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional Marketing Authorisation for BOSULIF, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion. |
| IB/0011               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 13/01/2015   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0013               | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)     | 23/12/2014   | 23/11/2015 | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0008               | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                             | 23/10/2014   | 26/02/2015 | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| PSUV/0007             | Periodic Safety Update                                                                                                                        | 09/10/2014   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0009               | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                          | 18/08/2014   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0001               | Update of sections 4.2, 4.4 and 5.2 of the SmPC                                                                                               | 22/05/2014   | 23/06/2014 | SmPC and PL | Based on population pharmacokinetic modelling, a daily                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|         | further to the results of study B1871020 in patients with renal impairment conducted as a post- authorisation measure (MEA 006) and population pharmacokinetic modelling. The Package Leaflet is updated accordingly. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            |            |                        | dose of 400 mg in patients with moderate renal impairment and a daily dose of 300 mg in patients with severe renal impairment are predicted to result in a similar AUC to that seen in patients with normal renal function receiving 500 mg daily. Consequently, in patients with moderate renal impairment (CrCL 30 to 50 mL/min, calculated by the Cockroft-Gault formula), the recommended dose of bosutinib is 400 mg daily (see sections 4.4 and 5.2). In patients with severe renal impairment (CrCL <30 mL/min, calculated by the Cockroft-Gault formula), the recommended dose of bosutinib is 300 mg daily (see sections 4.4 and 5.2). Dose escalation to 500 mg once daily for patients with moderate renal impairment or to 400 mg once daily in patients with severe renal impairment may be considered in those who did not experience severe or persistent moderate adverse reactions, under any of the following circumstances. Long-term treatment with bosutinib may result in a clinically significant decline in renal function in CML patients. It is important that renal function is assessed prior to treatment initiation and closely monitored during therapy with bosutinib, with particular attention to those patients exhibiting risk factors for renal dysfunction, including concomitant use of medicinal products with potential for nephrotoxicity, such as diuretics, ACE inhibitors, angiotensin receptor blockers and nonsteroidal   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0006 | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside                                                                                                                                                                                                                           | 22/05/2014 | 23/06/2014 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | the range of the currently approved pack sizes                                                                    |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------|-------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0005   | B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation | 13/05/2014 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUV/0003 | Periodic Safety Update                                                                                            | 10/04/2014 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| R/0002    | Renewal of the marketing authorisation.                                                                           | 21/11/2013 | 20/02/2014 | SmPC, Annex II and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Bosulif, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion. The product information has been updated in line with QRD template version 9. The details of the local representative in Croatia have been added in the package leaflet. |